PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech

TOKYO: TOKYO, Jan. 4, 2022 /PRNewswire/ -- PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Under the terms...

Click to view original post